Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Roshini Claire Anthony, 22 Feb 2017

Individuals with hepatitis C virus (HCV) infection who achieve a sustained virological response (SVR) have improved liver stiffness and a lower risk of hepatocellular carcinoma (HCC), according to a presentation at the Asian Pacific Association for the Study of the Liver annual meeting (APASL 2017) in Shanghai, China.

24 Feb 2017
Slideshow: Highlights from the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Shanghai, China, February 15 - 19.
Pearl Toh, 09 Mar 2017
Pearl Toh finds out from Professor Anna Lok, director of clinical hepatology at the University of Michigan in Ann Arbor, Michigan, US, on integrating guidelines, research data, and clinical setting in decision making for management of hepatitis B during the recent Asian Pacific Association for the Study of the Liver Annual Meeting held in Shanghai, China.

Albumin-bilirubin grade predicts prognosis in HCC

06 Jul 2017

Albumin-bilirubin (ALBI) grade may predict prognosis in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE), a new study shows.

The study included 881 HCC patients receiving TACE (median age 68 years; 76 percent male) and showing a median overall survival of 24 months. Hepatitis B (35 percent, n=311) and C (27 percent; n=241), and alcoholism (19 percent; n=162) were the principal causes of HCC.

Of all the tested markers, ALBI grade resulted in the highest homogeneity (43.655) and lowest corrected Akaike information criteria (AICc) value (8,094.296). This was followed by cirrhosis discriminant index (CDS; 35.635 and 8,102.143, respectively) and Child-Turcotte-Pugh score (CTP; 26.861 and 8,111.090, respectively).

Univariate survival analysis showed that alcoholism (hazard ratio [HR], 1.240; 95 percent CI, 1.018 to 1.509; p=0.032), alkaline phosphatase level (HR, 1.678; 1.435 to 1.963; p<0.001), vascular invasion (HR, 2.511; 2.075 to 3.039; p<0.001) and ALBI grades 2 (HR, 1.678; 1.421 to 1.981; p<0.001) and 3 (HR, 1.501; 1.251 to 1.801; p<0.001) were all indicators of poor prognosis.

Multivariate analysis confirmed the significant association of alkaline phosphatase level (HR, 1.362; 1.155 to 1.607; p<0.001), vascular invasion (HR, 1.999; 1.622 to 2.464; p<0.001) and ALBI grade 2 (HR, 1.531; 1.285 to 2.823; p<0.001) to reduced survival.

ALBI grade 3 (HR, 1.525; 0.976 to 2.382l; p=0.064) was only modestly associated with poor survival.

Participants with histologically confirmed HCC were recruited from the Taipei Veterans General Hospitals.

Aside from ALBI, CTP and CDS, the prognostic performances of the following liver reserve markers were also assessed: aspartate transaminase-to-platelet ratio (APRI), fibrosis index based on four factors (FIB-4), Göteborg University Cirrhosis Index (GUCI), model for end-stage liver disease (MELD) and Lok index.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Roshini Claire Anthony, 22 Feb 2017

Individuals with hepatitis C virus (HCV) infection who achieve a sustained virological response (SVR) have improved liver stiffness and a lower risk of hepatocellular carcinoma (HCC), according to a presentation at the Asian Pacific Association for the Study of the Liver annual meeting (APASL 2017) in Shanghai, China.

24 Feb 2017
Slideshow: Highlights from the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Shanghai, China, February 15 - 19.
Pearl Toh, 09 Mar 2017
Pearl Toh finds out from Professor Anna Lok, director of clinical hepatology at the University of Michigan in Ann Arbor, Michigan, US, on integrating guidelines, research data, and clinical setting in decision making for management of hepatitis B during the recent Asian Pacific Association for the Study of the Liver Annual Meeting held in Shanghai, China.